ReCode Therapeutics

ReCode is a biopharmaceutical company developing precision medicines for genetic respiratory diseases with significant unmet medical need.

ReCode’s diverse pipeline includes lead programs for primary ciliary dyskinesia (PCD) and nonsense mutations in cystic fibrosis (CF).

ReCode Therapeutics was founded in 2015 by Daniel Siegwart, Philip Thomas, and Michael Torres. The company is headquartered in Dallas, Texas and Menlo Park, California.

 

ReCode's diverse pipeline includes lead programs for cystic fibrosis (CF) caused by nonsense mutations, and primary ciliary dyskinesia (PCD). ReCode has developed a non-viral delivery therapeutic platform that enables it to precisely deliver its medicines safely and effectively.

 

ReCode's cystic fibrosis assets include RCT223, a transfer RNA (tRNA) approach, and RTX0001, a messenger RNA (mRNA) treatment. ReCode’s data showed that RCT223 was successful in restoring CFTR function in the gold-standard hBE cell model, both with single and repeat dosing.

 

ReCode’s Selective Organ Targeting (SORT) LNP platform offers several modes of administration and supports a range of genetic cargo, including mRNA, siRNA, DNA, gene correction components and mixed cargoes.

 

ReCode is backed by Pfizer Ventures, Leaps by Bayer, Amgen Ventures, OrbiMed, EcoR1 Capital, Sanofi Ventures, AyurMaya, Colt Ventures, Matrix Capital Management, MPM Capital, Vida Ventures, Hunt Technology Ventures, and others. The company raised $120M in an extended Series B round on Jun 29, 2022, brining the round total to $200M. The additional investment brings ReCode's total funding to $284M to date.

 

 

  • Year founded: 2015
  • Funding Info: $284M over 5 Rounds (Latest Funding Type: Series B)
  • Yearly Revenue: NA
  • Employee Size: 51-200
  • Business Valuation: NA
  • City/Town: Dallas
  • State: Texas
  • Country: United States
Related businesses